St. John of God Subiaco Hospital, Subiaco, Perth, Western Australia, Australia
Case Report
LSTA1 Potentiates Complete Response in Metastatic Gastroesophageal Adenocarcinoma
Author(s): Kristen K. Buck MD*, Andrew Dean MD and Tara McSweeney MD
Introduction: Gastroesophageal adenocarcinoma has an extremely poor prognosis and remains a major cause of cancer-related mortality worldwide. While chemotherapy remains the primary treatment for metastatic disease and improves survival overall, the prognosis for patients with gastroesophageal adenocarcinoma cancer remains poor; secondary to chemoresistance and limited targeted therapeutic approaches.
LSTA1 (certepetide) is a novel investigational drug designed to selectively target and enhance the uptake of anti-cancer drugs into solid tumours. Clinically, LSTA1 has demonstrated favourable safety, tolerability, and activity when added to gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Given its mechanism of action, LSTA1 is thought to be agnostic to the modality of therapeutics with which it is combined and could.. View More»